Search Results - "Trümper, Lorenz H."
-
1
A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients
Published in Haematologica (Roma) (01-11-2020)Get full text
Journal Article -
2
High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma
Published in Journal of clinical oncology (10-08-2010)“…Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL). A multicenter trial evaluated…”
Get full text
Journal Article -
3
MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
Published in Cancer research (Chicago, Ill.) (15-06-2019)“…Oncogenic MYC activation promotes proliferation in Burkitt lymphoma, but also induces cell-cycle arrest and apoptosis mediated by p53, a tumor suppressor that…”
Get full text
Journal Article -
4
A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients
Published in Haematologica (Roma) (01-11-2020)Get full text
Journal Article -
5
To irradiate or not to irradiate-that is the question
Published in Nature clinical practice. Oncology (01-02-2005)Get full text
Journal Article -
6
The EHA Research Roadmap: Malignant Lymphoid Diseases
Published in HemaSphere (01-06-2022)“…In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the…”
Get full text
Journal Article -
7
Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
Published in Blood (01-01-2001)“…Hodgkin lymphoma (HL) is characterized by the abnormal expression of multiple cytokines, accounting for its unique clinicopathologic features. We have…”
Get full text
Journal Article -
8
High-level DNA amplifications are common genetic aberrations in B-cell neoplasms
Published in The American journal of pathology (01-08-1997)“…Gene amplification is one of the molecular mechanisms resulting in the up-regulation of gene expression. In non-Hodgkin's lymphomas, such gene amplifications…”
Get full text
Journal Article -
9
Standard chemotherapy followed by allogeneic or autologous transplantation: The role of allogeneic transplantation in the AATT study
Published in Journal of clinical oncology (01-06-2022)“…7534 Background: Prognosis of relapsed and refractory T-cell lymphoma patients (pts) is devastating. Early results of the AATT study (Autologous or Allogeneic…”
Get full text
Journal Article -
10
Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA)
Published in Journal of clinical oncology (20-05-2020)“…Abstract only 8041 Background: Primary mediastinal B-cell lymphoma (PMBCL) is a distinct entity of aggressive lymphoma, which typically presents in young…”
Get full text
Journal Article -
11
Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL)
Published in Journal of clinical oncology (20-05-2015)“…Abstract only…”
Get full text
Journal Article -
12
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R 2 -CHOP in subjects with previously untreated, high-risk DLBCL
Published in Journal of clinical oncology (20-05-2019)“…Abstract only 7520 Background: We report results of a phase 2, open-label study of durvalumab (durva) in combination with R-CHOP or R 2 -CHOP (R-CHOP +…”
Get full text
Journal Article -
13
Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL)
Published in Journal of clinical oncology (20-05-2014)“…Abstract only…”
Get full text
Journal Article -
14
Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL)
Published in Journal of clinical oncology (20-05-2013)“…Abstract only TPS8611 Background: MTCL including systemic anaplastic large cell lymphoma (sALCL) are aggressive neoplasms. Anthracycline-based multiagent…”
Get full text
Journal Article -
15
Single-cell analysis of Hodgkin and Reed-Sternberg cells : molecular heterogeneity of gene expression and p53 mutations
Published in Blood (01-06-1993)“…We have used a single-cell based polymerase chain reaction (PCR) amplification technique to examine the gene expression pattern in single Hodgkin's and…”
Get full text
Journal Article -
16
Radioimmunotherapy efficiency and safety in consolidation and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: An updated analysis of 230 patients of the international RIT-network
Published in Journal of clinical oncology (20-05-2012)“…Abstract only 8052 Background: In aggressive lymphoma, few reliable clinical data about the use of radioimmunotherapy exist. Pts. with DLBCL registered in the…”
Get full text
Journal Article -
17
Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial
Published in Journal of clinical oncology (20-05-2016)“…Abstract only…”
Get full text
Journal Article -
18
The human germinal centre cells, follicular dendritic cells and germinal centre T cells produce B cell-stimulating cytokines
Published in Cytokine (Philadelphia, Pa.) (01-05-1995)“…Cytokine gene expression was investigated in the germinal centreconstituents of follicular dendritic cells and germinal centre T cells and compared to the mRNA…”
Get full text
Journal Article -
19
Identification of genetic imbalances in malignant lymphoma using comparative genomic hybridization
Published in Stem cells (Dayton, Ohio) (01-12-1995)“…In comparison to leukemias, the clinical relevance of chromosomal aberrations in non-Hodgkin's lymphoma (NHL) is not as well understood. This is primarily due…”
Get more information
Journal Article -
20
Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea
Published in Blut (01-02-1989)“…Treatment of the myeloid blast phase of chronic granulocytic leukemia is still a major problem in clinical hematology. Alternate-day plicamycin and hydroxyurea…”
Get full text
Journal Article